Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse

Annals of Oncology

Volumn 16, Issue 4, 2005, Pages 625-633

  Sureda, A ^a   Constans, M ^b   Iriondo, A ^b   Arranz, R ^b   Caballero, M D ^b   Vidal, M J ^b   Petit, J ^b   Lopez A ^b   Lahuerta, J J ^b   Carreras, E ^b   Garcia Conde J ^b   Garcia Larana J ^b   Cabrera, R ^b   Jarque, I ^b   Carrera, D ^b   Garcia Ruiz J C ^b   Pascual, M J ^b   Rifon J ^b   Moraleda, J M ^b   Perez Equiza K ^b   Albo C ^b   Diaz Mediavilla J ^b   Torres, A ^b   Torres, P ^b   Besalduch, J ^b   Marin J ^b   Mateos, M V ^b   Fernandez Ranada J M ^b   Sierra, J ^b   Conde, E ^b   more..

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b NONE

Author keywords

Autologous stem cell transplantation; First relapse; Hodgkin's lymphoma

Indexed keywords

CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOGRAFT; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WHOLE BODY RADIATION;

EID: 20944446433     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi119     Document Type: Article

References (31)

1. Longo DL, Young RC, Wesley M et al. Twenty years of MOPP therapy for Hodgkin's Disease. J Clin Oncol 1986; 4: 1295-1306.
2. Prosnitz LR, Farber LR, Kapp DS et al. Combined modality therapy for advanced Hodgkin's disease: 15 year follow-up data. J Clin Oncol 1988; 6: 603-612.
3. Longo DL, Duffey PL, Young RC et al. Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10: 210-218.
4. Bonfante V, Santoro A, Viviani S et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997; 15: 528-534.
5. Phillips GL, Wolff SN, Herzig RH et al. Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 1989; 73: 2086-2092.
6. Reece DE, Barnet MJ, Connors JM et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991; 9: 1871-1879.
7. Bierman PJ, Bagin RG, Jagannath S et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long term follow-up in 128 patients. Ann Oncol 1993; 4: 767-773.
8. Chopra R, McMillan AK, Linch DC et al. The place of high dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single center 8-year study of 155 patients. Blood 1993; 81: 1137-1145.
9. Crump M, Smith AM, Brandwein J et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol 1993; 11: 704-711.
10. Rapoport AP, Rowe JM, Kouides PA et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease for predicting outcome. J Clin Oncol 1993; 11: 2351-2361.
11. Nademanee A, O'Donell MR, Snyder DS et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood 1995; 85: 1381-1390.
12. Bierman PJ, Anderson JR, Freeman MB et al. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. Ann Oncol 1996; 7: 151-156.
13. Caballero MD, Rubio V, Rifón J et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20: 451-458.
14. Sureda A, Arranz R, Iriondo, A et al. Autologous stem cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the GEL/TAMO Spanish Cooperative Group. J Clin Oncol 2001; 19: 1395-1404.
15. Reece DE, Connors JM, Spinelli JJ et al. Intensive therapy with cyclophosphamide, carmustine, etoposide & cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1995; 83: 1193-1199.
16. Lohri A, Barnett M, Fairey RN et al. Outcome of treatment of first relapse of Hodgkin's after primary chemotherapy: identification of risks factors from the British Columbia experience 1970 to 1988. Blood 1991; 77: 2292-2298.
17. Yuen AR, Rosenberg SA, Hoppe RT et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89: 814-822.
18. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
19. Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy requiring autologous haemopoietic stem cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065-2071.
20. Brice P, Bouabdallah R, Moreau P et al. Prognostic factors for survival after HDT and ASCT for patients with relapsed HD: Analysis of 280 patients from the French Registry. Bone Marrow Transplant 1997; 20: 21-26.
21. Horning SJ, Chao NJ, Negrin RS et al. High-dose therapy and hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801-813.
22. Lancet JE, Rapoport AP, Brasacchio R et al. Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 1998; 22: 265-271.
23. Fermé C, Mounier N, Divine M et al. Intensive therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: Results of the Groupe d'Études des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002; 20: 467-475.
24. Carbone PP, Kaplan HD, Musshogg K et al. Report of the Committee of Hodgkin's Disease staging. Cancer Res 1971; 31: 1860-1861.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete estimations. J Am Star Assoc 1958; 53: 457-481.
26. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-1253.
27. Mantel N, Haenzel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1958; 22: 719-723.
28. Fung HC, Nademanee A, Krishnan A et al. Autologous hematopoietic cell transplantation (ASCT) for patients with chemo-refractory Hodgkin's lymphoma (HL). Blood 2003; 102: 119a (Abstr 404).
29. Josting A, Franklin J, May M et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the Database of the German Hodgkin's Study group. J Clin Oncol 2002; 20: 221-230.
30. Moskowitz CH, Nimer SD, Zelenetz AD et al. A 2-step, comprehensive high-dose chemotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97: 616-623.
31. Moskowitz CH, Kewalramani T, Nimer SD et al. Risk-adapted high dose chemoradiotherapy and ASCT for patients with relapsed or refractory Hodgkin's disease: An intent to treat analysis. Blood 2003; 102: 118a (Abstr 403).